Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Resmed ( (RMD) ) has provided an announcement.
On October 30, 2025, Resmed announced a quarterly cash dividend of $0.60 per share, payable on December 18, 2025, with a record date of November 13, 2025. The company also reported strong financial results for the first quarter of fiscal year 2026, with a 9% increase in revenue to $1.3 billion and a 15% rise in income from operations. Resmed’s performance reflects its strategic focus on transforming home healthcare, with significant growth in revenue and gross margin, driven by increased demand for its sleep devices and accessories.
The most recent analyst rating on (RMD) stock is a Buy with a $304.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.
Spark’s Take on RMD Stock
According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.
ResMed’s overall stock score is driven by strong financial performance and positive earnings call sentiment. The company’s robust revenue growth, profitability, and strategic investments in innovation are significant strengths. However, the high valuation and mixed technical indicators present some risks. The absence of notable corporate events further consolidates the focus on financial and operational metrics.
To see Spark’s full report on RMD stock, click here.
More about Resmed
Resmed Inc. operates in the healthcare industry, focusing on developing and manufacturing equipment related to sleep and respiratory care. The company provides solutions that help people sleep better, breathe better, and live healthier lives, with a significant emphasis on home healthcare solutions.
Average Trading Volume: 994,158
Technical Sentiment Signal: Buy
Current Market Cap: $37.01B
Learn more about RMD stock on TipRanks’ Stock Analysis page.